

To: Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

**CONTINUATION-IN-PART APPLICATION TRANSMITTAL**

Sir:

Transmitted herewith for filing is a **Continuation-In Part** patent application of:

**Serial No. 09/379,310**  
**Filed: August 23, 1999**  
**Group Art Unit: 1615**  
**Examiner: (not assigned)**

**Inventors:** William J. BOLOGNA, Howard L. LEVINE, and Dominique DE ZIEGLER

**Title:** BIOADHESIVE PROGRESSIVE HYDRATION TABLETS

**I. PAPERS ENCLOSED HEREWITH FOR FILING UNDER 37 CFR § 1.53(b):**

27 Pages of Written Description  
3 Pages Claims  
1 Page Abstract  
2 Sheets of Drawings ☐ Informal ☒ Formal

**II. ADDITIONAL PAPERS ENCLOSED IN CONNECTION WITH THIS FILING:**

- ☐ Declaration  
☐ Power of Attorney ☐ Separate ☐ Combined with Declaration  
☐ Assignment to \_\_\_\_\_ and assignment cover sheet  
☐ Verified Statement establishing "Small Entity" under 37 CFR §§ 1.9 and 1.27  
☐ Priority Document No(s):  
☒ Return Postcard

DC-1404.1

**CERTIFICATE OF DELIVERY**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being hand delivered on the date shown below to the Assistant Commissioner for Patents, Washington, D.C. 20231.

June 16, 2000  
Date of Delivery

William Winter  
Name of Person Delivering Paper

Wm Winter  
Signature of Person Delivering Paper

**III. THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:**

<b>BASIC FILING FEE:</b>						<b>\$690.00</b>
Total Claims	16	-	20	=	0 x \$18.00	0.00
Independent Claims	3	-	3	=	0 x \$78.00	0.00
Multiple Dependent Claims	\$260	(if applicable)			<input type="checkbox"/>	\$0.00
<b>TOTAL OF ABOVE CALCULATIONS</b>						<b>\$690.00</b>
Reduction by 1/2 for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28. If applicable, Verified Statement must be attached.						\$0.00
Misc. Filing Fees (Recordation of Assignment -- \$40)						\$0.00
<b>TOTAL FEES DUE HERewith</b>						<b>\$690.00</b>

**IV. METHOD OF PAYMENT OF FEES**

- ☐ A check in the amount of \_\_\_\_.
- ☒ **Charge Lyon & Lyon's Deposit Account No. 12-2475 in the amount of \$690.00.**
- ☐ This application is being filed without fee or Declaration under 37 CFR § 1.53.

**V. AUTHORIZATION TO CHARGE FEES**

The Commissioner is authorized to credit any overpayment and to charge any underpayment to Lyon & Lyon's Deposit Account No. **12-2475** for the following:

- ☒ 37 CFR § 1.16 – **(Filing fees and excess claims fees)**
- ☒ 37 CFR § 1.17 – **(Any application processing fees)**
- ☐ 37 CFR § 1.21 – **(Assignment recording fees)**

**VI. CORRESPONDENCE ADDRESS**

Please send all correspondence to Customer Number 22249:



**22249**

PATENT TRADEMARK OFFICE

LYON & LYON LLP  
Suite 4700  
633 W. Fifth Street  
Los Angeles, CA 90071


Please direct all inquiries to Suet Chong or Scott H. Blackman, at (202) 331-3600.

Respectfully submitted,

LYON & LYON LLP

Dated: June 16, 2000

By: \_\_\_\_\_

  
Scott H. Blackman  
Reg. No. 34,088

ATTY. DKT. NO. 254/304

APPLICATION FOR U.S. LETTERS PATENT  
OF  
WILLIAM J. BOLOGNA,  
HOWARD L. LEVINE  
AND  
DOMINIQUE DE ZIEGLER  
FOR  
BIOADHESIVE PROGRESSIVE HYDRATION TABLETS

LYON & LYON  
1701 Pennsylvania Avenue, N.W.  
Suite 1040  
Washington, D.C. 20006

## BIOADHESIVE PROGRESSIVE HYDRATION TABLETS

5 The present invention relates to a bioadhesive, bioerodible composition for the extended and controlled release of active ingredients. More particularly, the present invention relates to a progressive hydration tablet for adhesion to the wall of a body cavity for the sustained release of active ingredients without premature degradation of the active ingredients caused by metabolism, or by  
10 moisture, enzymes or pH effects.

15 Medications and other pharmaceutical products have traditionally been administered in doses via oral ingestion, nasal sprays or injections. These delivery methods have proven ineffective for patients needing a prolonged and constant supply of an active ingredient delivered to the bloodstream. Particularly difficult are patients needing dosing during sleep time hours. For these patients, intravenous venous ("IV") lines, slow-dissolving pills, and suppositories or transdermal patches have been prescribed.  
20 However, the inconvenience and discomfort of IVs, the short life span of many ingested active ingredients from gastrointestinal degradation or first-pass liver metabolism, and the inability of many products to be comfortably delivered transdermally in suitable doses or in controlled  
25 concentrations have proven these methods unsatisfactory.

30 Previous artisans have attempted to meet the needs of the art by developing products for the transmucosal administration of active ingredients. For example, certain active ingredients can be administered quickly into the bloodstream via the walls of a body cavity, such as the buccal or vaginal cavities, without the risk of first pass hepatic degradation. Generally, delivery of active ingredients through mucosal surfaces may be enhanced by the

use of bioadhesive formulations. However, one particular area where those in the art have attempted, but heretofore failed, to meet the needs of the art is in developing a bioadhesive tablet useful for sustained release applications without risking degradation of the active ingredient before it is actually released.

"Sustained release" generally refers to continuous or sporadic release of an active ingredient over an extended time after a single administration, whereby the level of active ingredient available to the host patient often is maintained at some constant level over a period of time. As used herein, it is also intended to cover the situation where the release of an active ingredient is controlled over a period of time wherein the level of active ingredient available to the host (bioavailability) may be at a variable but predetermined level at a particular instant in time of treatment.

The sustained release bioadhesive tablets known in the art can be generally broken down into two categories: (1) tablets consisting of water soluble carbomers, and (2) tablets consisting of insoluble polymers. Both types of tablets have proven unsatisfactory for many applications. For example, numerous artisans have attempted to formulate a suitable sustained release bioadhesive tablet from water soluble carbomers, such as carbomer 934P or CARBOPOL™ 974 resin (commercially available from B.F. Goodrich, Cleveland, Ohio). However, such tablets often are only able to adhere to the wall of a body cavity for short periods of time, e.g., six hours or less. Also, these tablets are easily dislodged from the wall of a body cavity and thus place patients using such tablets buccally at risk of asphyxiation. Furthermore, these prior art tablets inherently become hydrated relatively quickly and thus may

prematurely expose the reservoir of active ingredient to degradation by moisture or by enzymes from the host environment such as from bacteria in the septic oral or vaginal cavities.

5           Similarly, tablets comprised of insoluble polymers, such as polycarbophil, have proven unsuitable for many applications. For example, although polycarbophil tablets are capable of prolonged attachment to the wall of a body cavity, such tablets do not adhere immediately, making them  
10 impractical for certain treatments such a buccal delivery of active ingredients to patients during sleep time hours. Further, such tablets often do not soften sufficiently to provide comfort and imperceptibility, or provide safety from potential aspiration of the tablet.

15           Furthermore, for example, neither type of prior art tablet is particularly suitable for treating many conditions. As alluded to previously, there are numerous medical conditions in which a sustained and/or controlled release of active ingredient(s) is desired for any of  
20 numerous reasons including, for example, to alleviate the impact of first-pass hepatic metabolism of the active ingredient or the risk of premature degradation of the active ingredient by moisture, pH effects, or enzymes, or to attain the comfort and convenience offered by a suitable  
25 bioadhesive tablet. Such conditions include, but are not limited to, for example, those needing treatment with an active ingredient that may be, but is not limited to, a glycoprotein, protein, sex hormone, anti-hormone, nitrate, beta-agonist, beta-antagonist, opioid, opioid-antagonist,  
30 antidepressant, HMG CoA (3-hydroxy-3-methylglutaryl Coenzyme A) reductase inhibitor, antihistamine, ACE (angiotensin converting enzyme) inhibitor, and/or prostaglandin. Heretofore the art has required such patients to undergo the

more invasive and less suitable techniques and methods of delivery described above.

To illustrate the need in the art, consider hypogonadal men, for example. Hypogonadism in man is characterized by a deficiency or absence of endogenous testosterone production. Abnormally low levels of testosterone may place men at risk of "Andropause", wherein men are at greater risk of cardiovascular disease, Alzheimer's disease, and osteoporosis.

Testosterone has traditionally been used to treat hypogonadal men. However, to be most effective, the treatment must be capable of complete physiologic testosterone replacement. Moreover, the treatment must be capable of providing sustained levels of testosterone through the night, preferably sustaining a peak in the middle of the night. Transdermal testosterone patches typically produce only sub-physiologic levels and thus incomplete relief. Similarly, the prior art buccal tablets hereintofore described would be ineffective or impractical for such sustained testosterone delivery.

The hormone testosterone, like many other drugs, including many other proteins and glycoproteins, undergoes high first pass metabolism. Accordingly, as will be appreciated by one of ordinary skill in the art, buccal or vaginal tablets consisting of materials that are incapable of keeping the interior reservoir of the tablet in the dry state for prolonged periods are inherently incapable of preventing dissolution and swallowing or dissolution and rapid absorption through the mucosa of the active ingredient. Furthermore, as will be appreciated by one of ordinary skill in the art, tablets which are unable to quickly adhere to the target area or are able to become



dislodged are impractical for treatments which use night-time delivery, such as testosterone treatment.

Active ingredients such as testosterone may also undergo undesired metabolism. For example, 5 $\alpha$ -reductase converts testosterone to 5 $\alpha$ -dihydrotestosterone (DHT). DHT may cause adverse effects such as hair loss and prostate disorders. Similarly, 5 $\alpha$ -reductase may metabolize other active ingredients such as progesterone.

Various testosterone formulations have been developed to circumvent the problems inherent in rapid clearance of orally and parenterally administered agents. These include transdermal preparations (with or without emollient), pellets for subcutaneous implantation, biodegradable microcapsule formulations for injection, and inclusion complexes that enhance sublingual absorption of the hormone. Of these, the testosterone transdermal system for use on the scrotum and other skin patch products, are probably the most widely tested. Under optimal conditions, they are intended to approximate the physiological pattern of hormone levels throughout the day and provide an alternative to parenteral therapy.

However, the scrotal preparation causes a disproportionate increase in plasma dihydrotestosterone (DHT) to a level that is 30 to 40% that of testosterone, presumably because of the high level of 5 $\alpha$ -reductase in scrotal skin. Other skin patches likewise produce high levels of DHT. Such increases in serum DHT have also been reported after treatment with the extremely long-acting parenteral testosterone ester testosterone buciclate and with the oral ester testosterone undecanoate. Williams Textbook of Endocrinology, 9<sup>th</sup> Ed., W.B. Saunders Company, p. 853. Thus, the present invention advantageously avoids the

side effects that may be caused by 5 $\alpha$ -reductase's metabolism of active ingredients.

Furthermore, as will be appreciated by one of ordinary skill in the art, the advantages of a sustained release, bioadhesive tablet according to the present invention are not limited to the treatment of hypogonadism in men. For example, patients often require sustained release hormone treatment for various conditions. In addition, other medications, such as steroids for treating such conditions as asthma, involve treatments where desired peak levels are at night during sleep-time hours. Accordingly, one of ordinary skill in the art will appreciate that there exists a long-felt, yet unresolved, need to develop a bioadhesive, sustained release tablet to overcome the aforementioned needs of the art, including, but not limited to, the delivery of therapeutically effective amounts of an active ingredient which may be metabolized or otherwise degraded by moisture, enzymes, or pH effects, such as glycoproteins, proteins, sex hormones, anti-hormones, nitrates, beta-agonists, beta-antagonists, opioids, opioid-antagonists, antidepressants, HMG CoA reductase inhibitors, antihistamines, ACE inhibitors, and/or prostaglandins.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a series of photographs depicting the progressive hydration of a bioadhesive tablet according to the invention.

Figure 2 is a flowchart depicting a presently preferred method of making bioadhesive tablets according to the invention.

The present invention meets the aforementioned needs in the art. Accordingly, it is an object of the invention to provide a bioadhesive tablet that adheres immediately or almost immediately to the target tissue area of a body cavity and generally stays attached substantially throughout treatment. In accordance with this aspect of the invention, there is provided a bioadhesive tablet that can stay attached and deliver active ingredients in the buccal cavity for as much as eighteen hours or more. In accordance with a related aspect of the invention, there is provided a bioadhesive tablet that can stay attached and deliver active ingredients vaginally for as much as 72 hours or more.

It is another object of the invention to provide a bioadhesive tablet that progressively hydrates, whereby the inner core of the tablet remains protected from moisture and the surrounding environment. In accordance with this aspect of the invention there is provided a bioadhesive tablet suitable for sustained release use in mucosal and other body cavities even with active ingredients comprising proteins or glycoproteins or other treating agents that are particularly susceptible to metabolism, or to enzymatic, pH, or moisture-induced degradation.

It is a related object of the invention to provide a bioadhesive tablet having both controlled and sustained release properties due to a tablet formulation wherein the active ingredient is only progressively made bioavailable over an extended time period by the progressive hydration of the tablet's dry reservoir of active ingredient.

It is another object of the invention to provide a bioadhesive tablet according to the invention that also gelifies and/or swells to help protect a patient using the tablet buccally from asphyxiation, particularly a sleeping patient undergoing treatment.

It is yet another object of the invention to provide methods of making bioadhesive tablets in accordance with the aforementioned objects of the invention. In accordance with one aspect of the invention, there is provided a method of making bioadhesive tablets wherein an active ingredient resistant to premature metabolism and/or degradation is added in the first and/or second step (manufacture of granulate). In accordance with a related aspect of the invention there is provided a method of making bioadhesive tablets wherein an active ingredient prone to premature metabolism and/or degradation is added in the second step (manufacture of the tableting mixture) after the granulate is dried and sieved. Of course, other concerns or factors may affect the choice of which step or steps are appropriate for adding a particular active ingredient.

It is yet another object of the invention to provide methods of using bioadhesive tablets as described herein. In accordance with one aspect of the invention, there is provided a method of using a bioadhesive tablet to administer to a male patient a sustained release of testosterone. In accordance with a related aspect of the invention, there is provided a method of using a bioadhesive tablet to administer to a female patient a sustained release of a hormone, such as testosterone.

The inventors of the present invention have discovered, quite unexpectedly, that these and other objects for the invention may be achieved by making and using tablets comprising an active ingredient, water soluble polymers (e.g., CARBOPOL™ 974P), and insoluble polycarbophil (e.g., NOVEON®, available from B.F. Goodrich Specialty Polymers of Cleveland, OH), and preferably hydroxypropylmethyl cellulose (HPMC), lactose, corn starch and other standard tablets ingredients, such as magnesium stearate and talc.

Bioadhesive, progressive hydration tablets according to the invention may be used with any suitable active ingredient and may be used to deliver a therapeutic amount of the active ingredient to a patient at controlled rates for sustained periods of time. Tablets according to the invention may also be constructed in any suitable shape and any suitable size consistent with the intended therapeutic use of the tablet.

Tablets according to the invention may comprise any suitable amount of active ingredient. Suitable amounts of active ingredient according to the invention may be from minuscule amounts to about 50%, or more. As will be appreciated by one of ordinary skill in the art, "minuscule amounts" is intended to cover those amounts of active ingredient that are disproportionately small relative to the tablet, for example, when only a few micrograms of active ingredient are to be delivered via a tablet weighing over a hundred milligrams. Accordingly, one of ordinary skill in the art will appreciate that any amount of active ingredient, in any ratio, is within the scope of the present invention.

The balance of the tablet according to the invention may comprise water soluble polymer(s) and water insoluble cross-linked polycarboxylic polymer(s). Also, according to the invention, exemplary tablets preferably have between about 1% and about 75% by weight water soluble polymer and between about .5% and about 10% by weight water insoluble cross-linked polycarboxylic polymer. In accordance with the invention, such exemplary tablets also preferably include between about 5% and about 50% cellulose. Also in accordance with the invention, presently preferred tablets may have between about .5% and about 25% by weight starch.

These preferred tablets may also have between about 1% and about 50% by weight lactose.

Furthermore, according to the invention, preferred tablets may comprise from about .01% up to about 2% silica; and/or up to about .5% by weight talc; and/or up to about 2.5% by weight magnesium stearate.

Accordingly, one of ordinary skill in the art will appreciate that the components of the tablets can be varied to suit a particular purpose. For example, the inventors of the present invention have discovered, quite unexpectedly, that one way of increasing (decreasing) the time it takes a progressive hydration tablet to hydrate is by decreasing (increasing) the amount of lactose and/or starch and increasing (decreasing) the amount of water soluble polymer. Alternatively, the density of the tablet may be altered to affect the hydration period.

Active ingredients suitable for use in the present invention include any active ingredient or ingredients requiring sustained or controlled release, any active ingredient or ingredients requiring extended protection from premature degradation by moisture, pH effects, or enzymes, or any active ingredient requiring administration to a patient with protection from first-pass hepatic metabolism. Exemplary active ingredients suitable for use with the present invention include, but are by no means limited to: (1) glycoproteins, such as follicle-stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (HCG), thyroid-stimulating hormone (TSH), and the like; (2) proteins, such as GnRH (agonist and antagonist), oxytocin analogs, somatostatin analogs, tissue plasminogen activator (TPA), growth hormone releasing hormone (GHRH), corticotropin-releasing hormone analogs (CRH analogs), and the like; (3) sex hormones, such as estradiol,

testosterone, progesterone, and the like; (4) anti-hormones, such as tamoxifen, mifepristone, and the like; (5) nitrates, such as nitroglycerin, isosorbide, erythrityl tetranitrate, pentaerythritol tetranitrate, and the like; (6) beta-agonists, such as terbutaline, albuterol, pirbuterol, bitolterol, ritodrine, and the like; (7) beta-antagonists, such as propranolol, metoprolol, nadolol, atenolol, timolol, esmolol, pindolol, acebutolol, labetalol, and the like; (8) opioids, such as morphine, hydromorphone, oxymorphone, codeine, hydrocodone, oxycodone, leverophanol, levallorphan, buprenorphine, fentanyl, nalbuphine, butorphanol, pentazocine, and the like; (9) opioids-antagonists, such as naloxone, nalmeferene, and the like; (10) antidepressants, such as amitriptyline, amoxapine, desipramine, doxepin, imipramine, maprotilen, nortriptyline, protriptyline, trimipramine, fluoxetine, trazodone, and the like; (11) HMG CoA reductase inhibitors, such as lovastatin, mevastatin, simvastatin, pravastatin, atorvastatin, and the like; (12) antihistamines, such as loratadine, chlorpheniramine maleate, brompheniramine maleate, diphenhydramine, dimenhydrinate, carbinoxamine, promethazine, triprolidine, and the like; (13) ACE inhibitors, such as captopril, enalapril, lisinopril, and the like; and, (14) prostaglandins, such as misoprostol and the like.

Accordingly, one of ordinary skill in the art will appreciate that tablets according to the invention may be used with a wide variety of active ingredients to treat a wide variety of conditions.

The present invention also provides a pharmaceutical composition comprising:

an effective amount of active ingredient that is metabolized by 5 $\alpha$ -reductase,

a water insoluble, water-swellaable cross-linked polycarboxylic polymer, and

a water soluble polymer,

wherein said composition is formulated to deliver said active ingredient to the bloodstream of a mammal through a mucosal surface of the mammal.

The present invention further provides a method of delivering to a mammal an active ingredient that is metabolized by 5 $\alpha$ -reductase, comprising administering said active ingredient via a progressive hydration bioadhesive composition through a mucosal surface of the mammal.

In addition, the present invention provides a composition for delivering to the bloodstream of a mammal an active ingredient that is metabolized by 5 $\alpha$ -reductase, comprising:

a water insoluble cross-linked polycarboxylic polymer, and

a water soluble polymer,

wherein said composition is formulated to deliver said active ingredient through a mucosal surface of the mammal.

Preferably, the compositions of the present invention are formulated to deliver said active ingredient via the mammal's vaginal, buccal, nasal or rectal cavity.

The aforementioned and other aspects of the invention will become more clear by reference to the Figures and descriptions of preferred embodiments.

A preferred embodiment of the invention is depicted in Figure 1. As shown in the first-frame of Figure 1, before the tablet is administered all of the active is in the dry state and thus, not subject to the deleterious action of moisture, pH effects, enzymes or other chemicals. It is also not available for absorption (bioavailable). As shown in frames 2-6 of Figure 1, over time the residual portion of



the active remains in the dry state which both protects it from water and the immediate environment as well as allowing it to serve as a reservoir for the sustained and controlled release of the active. Such a delivery system is well suited for the delivery of proteins, glycoproteins, and other drugs which must be protected from metabolism or during prolonged administration from enzymatic, pH, or moisture-induced degradation.

In a preferred embodiment, when used buccally, progressive hydration of the bioadhesive tablet protects the patient, should the tablet become dislodged, by gelifying and becoming heavier and thus less likely to float in the airway, risking aspiration. This makes this embodiment particularly well suited for agents that should reach their peak levels in the middle of the night, e.g., hormones like testosterone or steroids to treat asthma. According to the invention, the hydration of the tablet can preferably take hours (e.g. 12 to 24 hours) when formulated for buccal tablets or even days when formulated for vaginal use. As will be appreciated by one of ordinary skill in the art, prior art bioadhesive tablets do not protect the active ingredient from moisture, pH, or from enzymes produced by bacteria in the septic oral and vaginal orifices.

Furthermore, as will be appreciated by one of ordinary skill in the art following the teaching of the present application, the tablet can be sized, shaped and dosed to meet the needs of the particular treatment being undertaken. For example, the buccal bioadhesive tablet depicted in Figure 1 was constructed to be only 9mm in diameter for the comfort of the patient, but made capable of delivering 7mg of testosterone per day, full physiologic level. By contrast, prior art transdermal patches were only capable of

delivering 5mg per day, in other words a sub-physiologic level.

A presently preferred method of manufacturing bioadhesive tablets is diagramed in Figure 2. The presently preferred method involves three steps as described below:

1. First step: manufacture of the granulate.

Hydroxypropylmethyl cellulose 15 000(=HPMC 15 000) is mixed with corn starch and lactose and in case of an active ingredient non sensitive to moisture the active is added. The mixture is wet with an aqueous solution of hydroxypropylmethyl cellulose 5 (=HPMC 5) and knead/granulated.

The granulate is dried in an oven under warm air (50 C) until moisture content is less than 2.5%

The dried granulate is broken with a stainless steel sieve oscillating granulator mesh size 1000 m.

2. Second step: manufacture of the tableting mixture.

Talc, silicon dioxide magnesium stearate, and in a case of an active sensitive to moisture, the active ingredient is added. All is sieved through a sieving machine having  
5 aperture size 500 m and then transferred into a free-fall mixer.

Addition of the granulate of step 1, followed by polycarbophil, carbomer and lactose. The whole is mixed until homogenous.

10

3. Third step: tableting

The tableting mixture is compressed into tablets by means of a rotative tableting machine equipped with punches 9mm flat on the upper side and curved ( $r=9\text{mm}$ ) on the lower  
15 side both with beveled edge. The tablets are dedusted and packed.

As depicted in Figure 2, an active ingredient that is non-sensitive to moisture is preferably added during the manufacture of the granulate. However, alternatively, the  
20 active ingredient can be added during the second step after the granulate is dried and sieved. Also, as will be appreciated by one of ordinary skill in the art, this second method is particularly preferred when the active ingredient  
25 is sensitive to moisture.

In a presently preferred manufacturing process, the active ingredient is preferably protected from moisture. A wet granulation is made of lactose, corn starch and HPMC. Testosterone, polycarbophil, carbomer 934P, talc and  
30 magnesium stearate are added dry for the final compression."

Furthermore, as will be appreciated by one of ordinary skill in the art following the teaching of the present application, the materials of construction can be varied to

optimize the desired characteristics of the tablet. For example, the present inventors have discovered that, quite unexpectedly, by progressively decreasing the amount of lactose and corn starch and progressively increasing the amount of carbomer 934P, the amount of time it takes a tablet to hydrate is progressively increased. Accordingly, as will be appreciated by one of ordinary skill in the art, tablets suited for specific treatments (i.e., specific active, specific dose, specific delivery time) can be manufactured.

These and other aspects of the invention may be more clearly shown by way of example.

EXAMPLE: TESTOSTERONE TABLET.

The following is an example of a formulation (Formulation 8, batch #00029906) designed for complete physiologic replacement of testosterone in men:

Testosterone	30.000 mg	24.0%
HPMC	26.250 mg	21.0%
Corn Starch	22.500 mg	18.0%
Monohydrated Lactose	30.125 mg	24.1%
Silica	1.250 mg	1.0%
Polycarbophil (Noveon)	3.125 mg	2.5%
Carbomer 974P	9.375 mg	7.5%
Talc	1.500 mg	1.2%
Magnesium stearate	0.875 mg	0.7%

Formulations like the one above produced sustained release in in-vitro dissolution tests. When used in female subjects formulas like this one also produce a sustained and controlled release of testosterone for 12 hours or more.

Formulations like the one above also provide a blood serum concentration ratio of testosterone to

5 $\alpha$ -dihydrotestosterone (DHT) of about 12 to 1 in the bloodstream of said mammal. It is contemplated that this serum concentration ratio preferably is about 10 to 1 or greater.

5 Table 1 depicts nine different formulations of bioadhesive tablets according to the invention. The active ingredient, testosterone, was held constant at 30.0 mg (24% by weight) so the effect of varying the proportions of the inactive ingredients could be studied.

10 The testosterone dissolution rates of selected formulations were then studied. Table 2 depicts the testosterone dissolution rate of six tablets selected from Formula 1, batch #0069904. Table 3 depicts the testosterone dissolution rate of six tablets selected from Formula 3, batch #0049904. Table 4 depicts the testosterone dissolution rate of six tablets selected from Formula 5, batch #0029904. Table 5 depicts the testosterone dissolution rate of Formula 6, batch #0019904.

15 The dissolution rate data was then graphed to illustrate the percent of testosterone released per hour. Chart 1 depicts the testosterone release rate for Formula 1 (see Table 2). Chart 2 depicts the testosterone release rate for Formula 3 (see Table 3). Chart 3 depicts the testosterone release rate for Formula 5 (see Table 4). Chart 4 depicts the testosterone release rate for Formula 6 (see Table 5).

Testosterone KT

	Form. 1		Form. 2		Form. 3		Form. 4		Form. 5		Form. 6		Form. 7		Form. 8		Form. 9	
	mg	%	mg	%	mg	%	mg	%	mg	%	mg	%	mg	%	mg	%	mg	%
Testosterone	30,000	24,00	30,000	24,00	30,000	24,00	30,000	24,00	30,000	24,00	30,000	24,00	30,000	24,00	30,000	24,00	30,000	24,00
HPMC 90SH-15000	31,250	25,00	30,000	24,00	28,750	23,00	27,500	22,00	26,250	21,00	25,000	20,00	23,750	19,00	22,500	18,00	21,250	17,00
Corn starch	2,500	2,00	7,500	6,00	12,500	10,00	17,500	14,00	22,500	18,00	27,500	22,00	32,500	26,00	37,500	30,00	42,500	34,00
Monohydrated lactose	11,375	9,10	13,875	11,10	16,375	13,10	18,875	15,10	21,375	17,10	23,875	19,10	26,375	21,10	28,875	23,10	31,375	25,10
Silica	1,250	1,00	1,250	1,00	1,250	1,00	1,250	1,00	1,250	1,00	1,250	1,00	1,250	1,00	1,250	1,00	1,250	1,00
Polycarbophil acid (Noveon AA-)	3,125	2,50	3,125	2,50	3,125	2,50	3,125	2,50	3,125	2,50	3,125	2,50	3,125	2,50	3,125	2,50	3,125	2,50
Carbomer 974 P	43,750	35,00	37,500	30,00	31,250	25,00	25,000	20,00	18,750	15,00	12,500	10,00	6,250	5,00	0,000	0,00	0,000	0,00
Talc	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70
Magnesium stearate	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70	0,875	0,70
Total Weight	125,000	100,00	125,000	100,00	125,000	100,00	125,000	100,00	125,000	100,00	125,000	100,00	125,000	100,00	125,000	100,00	125,000	100,00

TABLE 1

## TESTOSTERONE DISSOLUTION RATE

BATCH: 0069904

DISSOLUTION APPARATUS: ROTATING PADDLE 60 RPM / PLATINUM WIRE SPIRAL

SAMPLE	WITHDRAW (HOUR)	WITHDRAW (HOUR)	WITHDRAW (HOUR)	WITHDRAW (HOUR)	WITHDRAW (HOUR)	WITHDRAW (HOUR)	WITHDRAW (HOUR)
	0	1	2	4	6	8	24
1	0.0	0.7	1.9	7.6	10.6	16.0	88.6
2	0.0	0.6	1.7	6.7	11.7	18.0	88.5
3	0.0	0.7	2.0	6.9	11.2	17.1	88.3
4	0.0	0.6	1.7	7.0	10.9	17.0	87.4
5	0.0	0.7	1.9	6.8	12.4	18.3	86.6
6	0.0	0.7	2.1	6.6	11.4	17.4	86.6
AVERAGE VALUE	0.0	0.7	1.9	6.9	11.4	17.4	86.6

TABLE 2

## TESTOSTERONE DISSOLUTION RATE

0049904

BATCH :

DISSOLUTION APPARATUS :

ROTATING PADDLE 60 RPM / PLATINUM WIRE SPECTAL

SAMPLE	WITHDRAW (HOUR)	WITHDRAW (HOUR)	WITHDRAW (HOUR)	WITHDRAW (HOUR)	WITHDRAW (HOUR)	WITHDRAW (HOUR)
	0	1	2	4	6	8
1	0.0	0.9	3.1	5.6	10.6	16.5
2	0.0	1.1	3.1	5.6	10.5	16.9
3	0.0	1.2	3.4	6.3	11.8	18.0
4	0.0	0.9	2.9	5.4	10.8	16.7
5	0.0	1.1	4.9	5.7	10.6	16.8
6	0.0	1.0	2.9	5.6	11.0	16.9
AVERAGE VALUE	0.0	1.0	3.4	5.7	10.9	16.9
						24
						83.6
						82.2
						83.4
						82.7
						83.0
						83.6
						83.4

TABLE 3





### STEEL-TUBING WIRE SPIRAL

**BATCH:**

BATCH:  
DISSOLUT

0019904							
WATCH: DISSOLUTION APPARATUS: ROTATING PADDLE 60 RPM / PLATINUM WIRE SPIRAL							
SAMPLE	WITHDRAW (HOUR)		WITHDRAW (HOUR)		WITHDRAW (HOUR)		WITHDRAW (HOUR)
	0	1	2	4	6	8	24
1	0.0	1.2	2.1	5.9	11.1	16.1	71.7
2	0.0	0.8	2.0	5.0	9.7	14.1	70.1
3	0.0	0.9	2.3	6.4	11.3	15.8	74.6
4	0.0	0.9	2.0	5.5	10.4	15.0	68.6
5	0.0	0.8	1.8	4.9	9.9	14.6	76.6
6	0.0	0.9	1.8	4.9	9.1	13.1	70.3
AVERAGE VALUE	0.0	0.9	2.0	5.4	10.3	14.8	72.0

TABLE 5

# CHART 1

Formula 1

% of Testosterone released (dissolution / rotating paddle 60 rpm + platinum wire spiral)  
single value (n=6), Batch 0069904





CHART 2


% of Testosterone released ( dissolution / rotating paddle 60 rpm + platinum wire spiral )  
single value ( n=6 ), Batch 0049904



09395073, 051500

CHART 3

% of Testosterone released (dissolution / rotating paddle 60 rpm + platinum wire spiral )  
single value (n=6), Batch 0029904




Legend:  
 1 —◆— 2 —■— 3 —\*— 4 —x— 5 —\*— 6 —■—

09596073, 061500

CHART 4

% of Testosterone released ( dissolution / rotating paddle 60 rpm + platinum wire spiral )  
single value ( n=6 ), Batch 0019904



09396073, 061600

As shown in the charts and tables, by decreasing the amount of lactose and corn starch and increasing the amount of carbomer 934P, the time it takes for the tablet to hydrate is progressively increased. Formulation 1 (0069904) and others like it with high levels of carbomer 934P and low levels of lactose and corn starch are probably best suited for vaginal administration where release is often required over a period days. In the first example given above Formulation 8 (0029906), where the levels of lactose and corn starch are high and carbomer 934P is low, the formula is probably better suited to buccal administration where 12 hours of delivery is usually sufficient.

As will be appreciated by one of ordinary skill in the art, the examples and preferred embodiments are not intended to be limiting, and the invention applies to tablets comprised of any active ingredient and any combination of tablet materials. Furthermore, as will be appreciated by one of ordinary skill in the art, the invention is intended to cover the methods of manufacturing and therapeutic uses of the aforementioned tablets.

The invention being thus described, it will be apparent to those skilled in the art that the same may be varied in many ways without departing from the spirit and scope of the invention. Such variations are included within the scope of the appended claims.

All publications and patents or applications mentioned in this specification are herein incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference.

WE CLAIM:

1. A pharmaceutical composition comprising:  
an effective amount of an active ingredient that is  
5 metabolized by 5 $\alpha$ -reductase,  
a water insoluble, water-swellaable cross-linked  
polycarboxylic polymer, and  
a water soluble polymer,  
wherein said composition is formulated to deliver said  
10 active ingredient to the bloodstream of a mammal through a  
mucosal surface of the mammal.

2. The composition of claim 1, wherein said active  
ingredient is present in about 50% by weight or less.

3. The composition of claim 1, wherein said active  
ingredient is testosterone or progesterone.

4. The composition of claim 3, wherein said  
20 composition is formulated to deliver said active ingredient  
via the mammal's vaginal cavity.

5. The composition of claim 3, wherein said  
composition is formulated to deliver said active ingredient  
25 via the mammal's buccal cavity.

6. The composition of claim 3, wherein said active  
ingredient is testosterone and said testosterone is present  
in an amount of about 1% to about 30% by weight.

7. A method of delivering to a mammal an active  
ingredient that is metabolized by 5 $\alpha$ -reductase, comprising  
administering said active ingredient via a progressive



hydration bioadhesive composition through a mucosal surface of the mammal.

8. The method of claim 7, wherein the composition  
5 comprises:

a water insoluble, water-swellaable cross-linked polycarboxylic polymer,

a water soluble polymer, and

said active ingredient.

10

9. The method of claim 8, wherein said active ingredient is testosterone or progesterone.

10. The method of claim 9, wherein said active  
15 ingredient is testosterone, and said method provides a blood serum concentration ratio of testosterone to 5 $\alpha$ -dihydrotestosterone (DHT) of about 10 to 1 or greater in the bloodstream of said mammal.

20 11. A composition for delivering to the bloodstream of a mammal an active ingredient that is metabolized by 5 $\alpha$ -reductase, comprising:

a water insoluble cross-linked polycarboxylic polymer,  
and

25 a water soluble polymer,  
wherein said composition is formulated to deliver said active ingredient through a mucosal surface of the mammal.

12. The composition of claim 11, wherein said active  
30 ingredient is testosterone or progesterone.

13. The composition of claim 12, wherein said active ingredient is testosterone and said testosterone is present in an amount of about 1% to about 30% by weight.

5

14. The composition of claim 13, wherein said composition is formulated to provide a blood serum concentration ratio of testosterone to 5 $\alpha$ -dihydrotestosterone (DHT) of about 10 to 1 or greater in the bloodstream of said mammal.

10


15. The composition of claim 11, wherein said composition is formulated to deliver said active ingredient via the mammal's nasal cavity.

15


16. The composition of claim 11, wherein said composition is formulated to deliver said active ingredient via the mammal's rectal cavity.

## ABSTRACT OF THE DISCLOSURE


A bioadhesive composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).




FRAME 1




FRAME 2




FRAME 3



FRAME 4



FRAME 5



FRAME 6

FIG. 1




FIG. 2